Crohn's Disease and Colitis Trial, Not Yet Recruiting NCT05719766 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Not Yet Recruiting

NCT05719766
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been clinically diagnosed with Inflammatory Bowel Disease (IBD), based on specific diagnosis guidelines used in China.
  • People aged between 18 and 75 years old.
  • People who understand and agree to follow the study requirements and sign a consent form.
  • People who are identified as needing support or intervention based on a patient screening questionnaire.
  • People who are able to complete all training sessions and follow-up appointments required by the study.
  • People who enrol at least one year before the study ends, to allow enough time for follow-up.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are unable or unwilling to sign the consent form, or who are unable to follow the study procedures.
  • People who have had a stoma (an opening created surgically in the abdomen) or a specific type of bowel surgery called an ileorectal anastomosis.
  • People who do not complete their training sessions on time or do not fully complete all follow-up assessments.
  • People who have other cancers or serious, life-threatening complications alongside their IBD.
  • People who are pregnant or breastfeeding.
  • People who would have less than one year of follow-up time remaining before the study ends.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yan chen, Second Affiliated Hospital, School of Medicine, Zhejiang University

Phone: +8613757118653

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 April 2023
Est. completion
1 January 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Improved score of Quality of Life after three months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov